Member Info for SYN00GOLD

Afternoon Synners and Happy New Year.

Well, we have an awful lot to look forward to in the next couple of months. I must say I was quite surprised that RM was not in a position to release news of 1st patient dosed in P3 in Q4 2020, but then I was also wondering have a large Pharma been actively negotiating in the background from the USA. Potentially already dosing, as technically this dosing does not have to be officially RNS'd. (only significant results). I wonder also that the home trial is probably in the closing stages now and the staff probably have a good understanding of the outcome from the completed patients already dosed. The USA will have a strong handle on the criticality of SNG001 and its therapeutic benefits at this juncture in the crisis.
I believe all the vaccine news is now out of the way and going forward Synairgen news will come thick and fast.

As has been mentioned by pmjh, Elsol, Ox, Bitethebull et al the list of positives and release of RNS'able material is significant going forward.

The most significant data to me personally is the sheer strength of the P2 data which Professor Holgate stated as 'best in class around the world for Covid 19 trials'. I think the probability of these results not being replicated to achieve statistical significance is now extremely low.

I agree with Elsol that the chance of P3 success is >90%.

Key now for me is not the announcement of 1st P3 dose, but potentially expedited announcement of home trial data and then EUA from FDA. From a commercial perspective, I think SP will be on a strong trajectory henceforth and we are in a wonderful position of strength.

Take care and stay safe. Looking forward to the coming months from a share perspective, BUT not the horrors that the country will have to endure to get through these winter months.

RM quoted cost of P3 was circa £30million with 900 patients. With removal of the lower dose arm and now 610 patients, this should give RM another approximately £10 million for ramping up production.

I have to agree with Vorag - I believe we will over the next 6 months follow a similar trajectory to the graph that took place with Novacyt. I hope for a JV as best scenario and £8 by late spring/early summer (pending +ve outcome !!) :-)

pmjh - You have done some brilliant investigatory work this year. Take a bow fella. Thank you.

Happy New Year to all.

Lets see the cronyism of Matt Han**** now in action............

Totally agree Big. USA are in more dire straits than UK (if that is possible !). This is ONLY going to solved by multiple combinations of therapeutics and vaccines. Story below explains real life effects of C19

https://www.nytimes.com/2020/12/30/health/covid-hospital-readmissions.html?action=click&module=Top%20Stories&pgtype=Homepage

Keep safe, we have an awful long way to go and SNG001 will have a very strong place in markets worldwide.

Agree with all those comments Doc 100%. Just been watching news updates, NHS England's chief executive Simon Stevens said health workers were "back in the eye of the storm".
He told BBC Radio 4's Today programme: "We're going to need decisive, early, national action to prevent a catastrophe in January and February."

The "50% increase in transmissibility" of the new variant means that "the previous levels of restrictions that worked before won't work now, and so tier four restrictions are likely to be necessary - or even higher than that", he added.

Tier four - England's toughest level of coronavirus restrictions, currently in place in parts of east and south-east England - includes a "stay at home" order and the closure of non-essential shops.

Prof Hayward, a professor of infectious disease epidemiology at University College London, said: "I think we're really looking at a situation where we're moving into near lockdown."

Dacourum- I'm no cactus expert, but I know prick when I see one. Filturd to my green bin. Bye.

I have this incredible ability to predict what’s inside a wrapped present.

It’s a gift.

You can groan now :-) See you all tomorrow.

Doc - you gave me a chuckle !!!!! :-)

Hopefully some more merriment tomorrow with 1st patient dosed...…………………..maybe...….imminent......or something like that.

I just find it a crying shame that SNG001 could actually be saving many lives currently and alleviating a lot of suffering and long Covid cases. These will be a terrible cost on the NHS both emotionally and financially.

https://www.bbc.co.uk/news/uk-55462701

I would guess it has already happened too. If Parexcel cannot get this set up in the current pandemic environment, with such huge volumes of patients overloading hospitals worldwide.....................

I'm positive based on their previous track record. looking forward to Easter and some rather large snippets of news. For the present, just a 1st dose RNS.

Hi Matml74 - Always love your posts, direct and clear without BS (sometimes I slide into ramping !!)

A close friend of mine reviewed the lancet paper (she is a statistician). Her view was that although quite small population, the critical, and good thing that Synairgen did, was to factor into the stats model, as best possible, the variations between both groups and all variations in comorbidities. Therefore, on balance and that is why, I believe it is fantastic that the FDA/EMA/MHRA have had the opportunity to review all data to date:
The primary endpoint was the change in clinical condition using the WHO Ordinal Scale for Clinical Improvement (OSCI) during the dosing period in the intention-to-treat population (ITT).

SNG001 was shown to be well tolerated and patients who received the drug had greater odds of improvement and recovered more rapidly. Patients receiving SNG001 had greater odds of improvement across the OSCI scale (OR 2·32; 95% CI: 1·07, 5·04; p=0·033) and were more likely to recover to "no limitation of activity" during treatment (HR 2·19; 95% CI: 1·03, 4·69; p=0·043). There were three deaths in the placebo group and none in the SNG001 group.

Her view is that, the additional data sets that these agencies have at their disposal should give investors some assurance.

It has for me :-)

I think sentiment will play a part this week with the MHRA news released of vaccine from AZ. Although this should (this time around be minimal). I will not be taking the risk of day trading. This is a long term play and IMHO will reap large rewards.

Ted - it is on the back page of the Business and money section (in my paper copy of Times)

Agree John - Nice to be getting a very positive review of Synairgen on the pages of the Sunday Times. As the author says, it IS going to be one of the biggest success stories EVER for the treatment of respiratory diseases !!!!!!
Zwarts - I have just scanned the BB over the past couple of days and my screen is completely strewn with little green boxes and 1 post derampers. I do agree that they are attempting an orchestrated rally to put fear into investors to sell shares and mop up as many loose shares as they possibly can, which can only infer one conclusion...………...…...……..

HOLD, HOLD, HOLD...………….this share is rock solid gold. Science is brilliant as are all results to date. The FDA have given Fast track status to the drug and we will have announced first dose 'imminently' in P3. I will say again, the more vaccines against Covid and any variants the better. These and therapeutics will ALL be needed to save lives !!!!

Wishing all a very happy and healthy 2021. Keep safe and ignore the 'noise'

'Pulmogen'

Now that is a first !!!

https://www.fool.co.uk/investing/2020/12/23/synairgen-shares-heres-why-i-think-the-stock-could-double-in-2021/

Richard Marsden just waiting to get the confirmation from one of the hospital Principal Investigators informing him of start of dosing in one of the testing sites. Relax. RNS imminent.

Some large delayed trades = good news and just to wrap of a successful last few weeks can I just indulge you all in a snippet from the last RNS which is luvvly jubbly:

Richard Marsden, CEO of Synairgen, said: "With this adaptation we should be able to reduce the time taken to complete the trial, which, together with an expedited review from the FDA, could allow us to get this therapy approved for patient use in COVID-19 more rapidly. With trial sites now being set up, we anticipate dosing the first patients imminently. SNG0011 is one of the few potential treatments to have shown efficacy against severe viral lung infections such as COVID-19, and multiple approaches will be needed to minimise the impact of this deadly virus.



"There remains a great need to develop breakthrough treatments for patients who become ill with COVID-19, despite the recent successes from the vaccine developers. This is especially important if vaccine uptake is poor for any reason, or if any mutations in the SARS-CoV-2 virus render the vaccines less effective."

Till tommorow..............HOLD, HOLD, HOLD :-)

I've just had a little top up, way SNG heavy, probably should go on a diet, but will consider my health after P3 results :-)

Well said 1509 :-)